Skip to main content

Ultrafiltration Method for siRNA PPB Evaluation

The ultrafiltration method is a widely used technique for assessing plasma protein binding (PPB) of siRNA molecules, including those conjugated with GalNAc. This method separates free (unbound) siRNA from protein-bound siRNA, enabling quantification of the unbound fraction. Here’s a detailed look at the ultrafiltration method, particularly for siRNA molecules, which can pose unique challenges due to their size, charge, and potential for non-specific binding.

Steps in Ultrafiltration Method for siRNA PPB Evaluation

  1. Preparation of Plasma-siRNA Mixture:

    • Dilute siRNA Sample: The test siRNA is diluted in plasma to achieve a physiologically relevant concentration.
    • Equilibration: The plasma-siRNA mixture is incubated, typically at 37°C, to allow binding equilibrium between the siRNA and plasma proteins (e.g., albumin, α-1 acid glycoprotein).

  2. Ultrafiltration Device and Membrane Selection:

    • Device: Specialized ultrafiltration devices (e.g., Amicon, Centrifree) are used to separate free siRNA from protein-bound siRNA.
    • Membrane Pore Size: A membrane with a molecular weight cut-off (MWCO) of approximately 30 kDa is usually chosen for siRNAs, as they generally have a molecular weight around 13-15 kDa. This ensures that only free siRNA can pass through while protein-bound siRNA complexes (typically >30 kDa) are retained.

  3. Centrifugation:

    • Centrifuge the Mixture: The plasma-siRNA mixture is centrifuged at a low speed, enough to allow free siRNA to pass through the membrane but not high enough to cause non-specific interactions or aggregation.
    • Collect Filtrate: The ultrafiltrate containing free siRNA is collected from the device’s lower chamber. This step is often carefully optimized to avoid non-specific adsorption of siRNA to the membrane.

  4. Quantification of Free siRNA:

    • Detection Method: Quantify the concentration of siRNA in the ultrafiltrate using quantitative PCR (qPCR), high-performance liquid chromatography (HPLC), or liquid chromatography-mass spectrometry (LC-MS).
    • Total siRNA Measurement: To calculate the free fraction, it’s essential to also measure the total siRNA concentration in a non-filtered plasma sample as a control.
    • Calculation: The percentage of unbound siRNA is calculated as: Unbound Fraction (%)=(Concentration of Free siRNA in FiltrateTotal Concentration of siRNA in Plasma)×100\text{Unbound Fraction (\%)} = \left( \frac{\text{Concentration of Free siRNA in Filtrate}}{\text{Total Concentration of siRNA in Plasma}} \right) \times 100

  5. Repeat for Replicates and Controls:

    • Replicates: Conduct multiple replicates to ensure data reliability.
    • Non-specific Binding Controls: Test the siRNA in buffer-only samples without plasma proteins to identify any non-specific membrane adsorption.

Challenges and Optimizations in Ultrafiltration for siRNA

  1. Non-specific Binding to the Membrane:

    • siRNA molecules can adsorb to ultrafiltration membranes due to electrostatic interactions or hydrophobic effects, leading to an underestimation of the unbound fraction. This is especially true for GalNAc-siRNAs, which have modified structures.
    • Mitigation: Pre-coating membranes with albumin or other inert proteins can reduce non-specific binding.

  2. Adsorption to Plasma Proteins:

    • Non-specific interactions between siRNA and plasma proteins other than the intended targets may occur. This could give a misleadingly high binding percentage if not controlled.
    • Mitigation: Optimization of the incubation period and the use of competitive binding studies help in discerning specific vs. non-specific protein interactions.

  3. Influence of pH and Temperature:

    • siRNA-protein binding can vary with pH and temperature, so maintaining physiological conditions (e.g., pH 7.4, 37°C) is important to reflect in vivo binding conditions accurately.

  4. Consideration of Charge and Hydrophobicity of siRNA:

    • siRNAs with charged modifications or conjugations, like GalNAc, may interact differently with plasma proteins or membranes than unmodified siRNAs.
    • Optimization: Adjust incubation time and use specific binding buffers to minimize alterations to protein-siRNA interactions.

Interpreting Ultrafiltration Results for siRNA PPB

  • High Binding (>95%): Indicates extensive plasma protein binding, suggesting a reduced free fraction available for liver targeting but potentially prolonged circulation.
  • Moderate Binding (50–90%): Suggests a balanced profile with some free siRNA available for hepatocyte uptake while maintaining adequate circulation stability.
  • Low Binding (<50%): Indicates higher free siRNA levels, which may enhance liver targeting but also increase the risk of rapid clearance.

Ultrafiltration provides a useful method for evaluating the PPB of GalNAc-siRNAs, offering insights into their pharmacokinetic behavior and enabling more accurate predictions of their distribution, clearance, and potential therapeutic efficacy

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases oft...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2): 1. Purpose of ICH Q8 (R2): The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities. 2. Scope: ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products. 3. Pharmaceutical Develop...
Read more